布地奈德与孟鲁司特钠联合治疗咳嗽变异性哮喘疗效观察

Observation on the effect of budesonide combined with montalukast in the treatment of cough-variant asthma

目的观察孟鲁司特钠、布地奈德联合治疗小儿咳嗽变异性哮喘的疗效。方法选取2015年4月至2016年5月登封市人民医院儿科收治咳嗽变异性哮喘患儿86例为研究对象,随机分为观察组和对照组各43例。对照组用布地奈德治疗,观察组加用孟鲁司特钠治疗,7d为1个疗程,治疗2个疗程后对疾病治疗效果进行评估,检测治疗前后患儿白细胞介素8(IL-8)、白细胞介素4(IL-4)水平变化情况。结果观察组总有效率为97.7%(42/43),对照组总有效率为86.0%(37/43),两组比较差异无统计学意义(P>0.05);治疗前两组患儿血清中炎症因子IL-8、IL-4水平比较差异无统计学意义(P>0.05),用药后观察组IL-8、IL-4值显著低于对照组,差异有统计学意义(P<0.05)。结论临床以孟鲁司特钠、布地奈德联合用于小儿咳嗽变异性哮喘治疗,患儿恢复好、炎症消失快。

Objective To observe the effect of budesonide combined with montelukekast in the treatment of children with cough-variant asthma. Methods A total of 86 children admitted to the Pediatric De- partment of Dengfeng People＇s Hospital and treated for cough-variant asthma from April 2015 to May 2016 were chosen as the research subjects, and they were randomly divided into observation group and control group, 43 in each group. The control group was treated with budesonide, which the observation group was treated with montelukast in addition to budesonide, 7 days as a course of treatment. After two courses, the clinical effect was evaluated, and the changes of IL-8 and IL-4 level were detected before and after treat- ment. Results The total effective rate was 97.7%（42/43） in the observation group and 86.0%（37/43） in the control group, the difference was of no statistical significance（P〉0.05）. The level of IL-8 and IL-4 before treatment had no statistical difference（P〉0.05）, but after treatment, their levels in the observation group were significantly lower than those in the control group, and there was statistical difference（P〈0. 05）. Conclusion The combination therapy with montelukast and budesonide has good effect in the treatment of children with cough-variant asthma; the children recovered sooner and the inflammation is relieved earlier.